Aducanumab receives FDA Approval

First Alzheimer’s treatment to slow disease progression receives FDA approval on 07 June 2021

Aducanumab, the first disease modifying treatment for Alzheimer’s disease, which was tested through clinical trials at Re:Cognition Health’s centres, has received landmark FDA approval as the first successful medication to treat the underlying cause of Alzheimer’s and thereby  slow down  progression of the disease and its symptoms.

The ground-breaking research was conducted through a series of international clinical trials over more than a decade and demonstrates the power and importance of clinical trials as evidenced, recently, through the rapid development of the Covid vaccine.

Aducanumab, targets the amyloid plaque, one of the main causes of Alzheimer’s. When Beta-amyloid (Aβ) plaques accumulate in the brain and are not cleared, effectively, they prevent the cognitive brain cells from working normally which eventually leads to the destruction of these important brain cells. Aducanumab is designed to increase the clearance of this excess amyloid from the brain and hence to slow down both the destruction of brain cells and the progression of Mild Cognitive Impairment, due to Alzheimer’s.

Dr Emer MacSweeney, CEO and Medical Director at Re:Cognition Health comments, “We are absolutely thrilled to be involved in the clinical development programme of Aducanumab and delighted for what this means to people living with Alzheimer’s disease and their families, for whom this  signifies the beginning of a new future for this common condition. We hope it will give confidence to millions of people who are worried about their memory and encourage them to seek an early and accurate diagnosis, so they too can potentially benefit from these new generation medications. We are so grateful to all of the volunteers who participate in clinical trials at Re:cognition Health and proud of the progress we are all making, together.”

Dementia is the only cause of death still on the rise and Alzheimer’s disease is the most common cause. Every 3 seconds someone in the world develops dementia and without effective treatments, 1 in 3 people born today will die with dementia, making it one of today’s biggest global socio-economic and health care crisis. With every clinical trial conducted, we understand more about the disease and get closer to unlocking new treatments.

To understand how it is possible to access this new type of medication in the UK, today, please follow this link https://recognitionhealth.com/clinical-trials-registration/